Jiangsu Hengrui Pharmaceuticals (SHA:600276) unit Suzhou Sundia Biopharmaceuticals obtained the approval of China's drug regulator to begin clinical trials for SHR-3079 injection.
The drug is indicated to treat B-cell non-Hodgkin's lymphoma, according to a Thursday filing with the Shanghai bourse.
Shares of the pharmaceutical company were down 1% Friday.
Jiangsu Hengrui Pharmaceuticals (SHA:600276) unit Ruishi Biopharmaceuticals obtained the approval of China's drug regulator to begin clinical trials for RSS0393 Latex.The drug is indicated to treat atopic dermatitis, according to a Friday filing with the Shanghai bourse.Shares of the pharmaceutical company were down 1% Friday.
Endurance Technologies' (NSE:ENDURANCE, BOM:540153) consolidated profit attributable to the owners increased to 2.76 billion Indian rupees in the fiscal fourth quarter from 2.45 billion rupees a year ago, according to a Thursday filing to the Indian stock exchanges.Shares of the company fell over 5% in Friday's trade.Earnings per share for the quarter ended March 31 climbed to 19.65 rupees from 17.43 rupees a year earlier.Revenue from operations of the aluminum die-casting company jumped year on year to 40.9 billion rupees from 29.6 billion rupees, the filing said.The board of Endurance Technologies declared a dividend of 11.50 rupees per share for the fiscal year ended March 31.
AJJ Medtech's (SGX:584) attributable loss to equity holders widened to SG$563,000 in the first quarter from SG$234,000 a year earlier, according to a Thursday filing with the Singapore Exchange.Shares of the healthcare technology company sank nearly 17% in Friday trading.Loss per share came in at SG$0.00033 compared with SG$0.00016 in the year-ago period.Revenue declined 51% year over year to SG$465,000 from SG$945,000.